Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver,
today announced that it has entered into a collaboration and option agreement with Heqet Therapeutics s.r.l. (“Heqet”) utilizing the Company’s proprietary OligoPhoreTM delivery platform.
Based in Turin, Italy, Heqet is a biotech spin-out from King’s College London. It is developing groundbreaking genetic medicines to reverse the damage of ischemic heart disease.